AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Prime Therapeutics stock surges 35% on JonesTrading's acquisition optimism.
ByAinvest
Monday, Jul 7, 2025 12:37 pm ET1min read
Prime Therapeutics (NASDAQ:PRME) shares rose by around 35% on Monday following a bullish report from JonesTrading. The report highlighted increased interest in gene editing due to Eli Lilly's recent deal to pay up for a gene editing platform. JonesTrading sees Prime Medicine as a potential acquisition target.
Prime Therapeutics (NASDAQ: PRME) shares rose by around 35% on Monday following a bullish report from JonesTrading. The report highlighted increased interest in gene editing due to Eli Lilly's recent deal to pay up for a gene editing platform. JonesTrading sees Prime Medicine as a potential acquisition target.The gene editing sector has seen significant momentum, with several acquisitions and increased investor interest. Eli Lilly's recent acquisition of Verve Therapeutics (NASDAQ: VERV) for $1.3 billion has further fueled this interest. Prime Medicine's shares have surged approximately 160% since mid-June, building on momentum that began after a management change on May 19 [2].
Several factors appear to be driving Prime Medicine’s upward trajectory. These include Eli Lilly’s acquisition of Verve Therapeutics, a significant price/valuation discrepancy compared to peers, substantial insider buying of 329,000 shares in the open market since mid-May, and high short interest exceeding 30% of float [2].
Jones Trading analyst Soumit Roy commented on the sector’s outlook: "VERV’s Phase 1b data was sufficient to trigger an M&A, and we believe PRME could get to the same place as they start announcing their clinical data in 2027" [2].
While Prime Medicine has yet to produce clinical data, Lilly’s acquisition of Verve suggests pharmaceutical companies are increasingly interested in gene editing technologies for treating larger market diseases, not just rare conditions with acute unmet needs [2].
Prime Therapeutics appears well-positioned to benefit from the ongoing momentum in the gene editing sector. With substantial cash reserves and a strong pipeline, the company is poised to capitalize on the growing interest in this technology.
References:
[1] https://www.investing.com/news/stock-market-news/prime-medicine-stock-soars-amid-gene-editing-sector-momentum-4125209
[2] https://www.asktraders.com/analysis/summit-therapeutics-stock-smmt-new-bullish-price-target/
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet